INFORMATION BY CANCER TYPE
The FDA recently issued a warning that a type of medicine used to treat Type 2 diabetes may increase a person's risk for developing bladder cancer.
Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.
The PD-L1 inhibitor durvalumab was granted a priority review for the treatment of some patients with urothelial carcinoma.
As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.
The treatment landscape of bladder cancer drastically changed this spring with the approval of an immunotherapy agent, and will continue to shift in the months and years to come.
One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage.
The combination of Opdivo and Yervoy is showing promise in the treatment of bladder cancer, according to a recent study.
The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.
A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.
When it comes to bladder cancer, PD-1 and PD-L1 agents will become the new mainstay, says Jonathan E. Rosenberg, M.D.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Bladder Cancer Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of bladder cancer.
Gallbladder Cancer Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of gallbladder cancer.